NEUMORA THERAPEUTICS, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 30 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-12-11: Reporting owner Duncan Jason; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-09-18: Reporting owner Milligan Michael Lee; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
- 2023-09-18: Reporting owner Milligan Michael Lee; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
- 2023-09-18: Reporting owner Milligan Michael Lee; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-12-11 | Duncan Jason Officer (Chief Legal Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +400,000 400,000 owned after | $12.97 exercise price | $12.97 | 2023-12-12 |
| 2023-09-18 holding as of filing | Milligan Michael Lee Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.63 exercise price | 2023-09-18 | ||
| 2023-09-18 holding as of filing | Milligan Michael Lee Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.52 exercise price | 2023-09-18 | ||
| 2023-09-18 holding as of filing | Milligan Michael Lee Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.36 exercise price | 2023-09-18 | ||
| 2023-09-14 | Lenz Robert A. Officer (Head of R&D) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +502,934 502,934 owned after | $17.00 exercise price | $17.00 | 2023-09-18 |
| 2023-09-14 | Piacquad David Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,455 46,455 owned after | $17.00 exercise price | $17.00 | 2023-09-18 |
| 2023-09-14 | Burow Kristina Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,455 46,455 owned after | $17.00 exercise price | $17.00 | 2023-09-18 |
| 2023-09-14 | Halawa Alaa Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,455 46,455 owned after | $17.00 exercise price | $17.00 | 2023-09-18 |
| 2023-09-14 | Fust Matthew K Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,802 27,802 owned after | $17.00 exercise price | $17.00 | 2023-09-18 |
| 2023-09-14 | Ho Maykin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +27,802 27,802 owned after | $17.00 exercise price | $17.00 | 2023-09-18 |
| 2023-09-14 holding as of filing | Aurora Daljit Singh Officer (Chief Strategy Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.24 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Aurora Daljit Singh Officer (Chief Strategy Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.52 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Aurora Daljit Singh Officer (Chief Strategy Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.36 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Ho Maykin Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.52 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Suh Carol Y. Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.52 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Suh Carol Y. Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.63 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Suh Carol Y. Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.52 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Suh Carol Y. Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.36 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | BERNS PAUL L Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $10.83 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | BERNS PAUL L Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.63 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | BERNS PAUL L Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.36 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Gosebruch Henry O Director, Officer (President & CEO) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.36 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Fust Matthew K Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $8.32 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Fust Matthew K Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $8.79 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Fust Matthew K Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.52 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Pinto Joshua Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.52 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Pinto Joshua Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.52 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Pinto Joshua Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.52 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Pinto Joshua Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.63 exercise price | 2023-09-14 | ||
| 2023-09-14 holding as of filing | Pinto Joshua Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.36 exercise price | 2023-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |